Kopran Limited
Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacture and supply International Quality Formulations and Active Pharmaceutical Ingredients worldwide.
What Kopran files
- Others45
- Board Meeting9
- JV/Acquisition6
- PPTs6
- Investor Meet6
- Important5
Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Kopran Limited has submitted their...
Proceedings of AGM, Voting result and Scrutiniser's report.
Kopran Limited has informed the Exchange about Copy of Newspaper Publication
Kopran's Q1 FY26-27 revenue climbed 13.88% YoY to **153.99 Cr** (from 135.22 Cr). EBITDA also rose 11.13% YoY, hitting **15.88 Cr**. However, Net Profit dipped 10.19% YoY to **6.70 Cr**, with EPS at Rs. 1.39. The API segment was the largest contributor with **95.38 Cr** revenue, while Formulations generated **57.09...
Kopran Ltd's board approved Q1 financial results. Consolidated revenue for the quarter rose to Rs 153.99 Cr, up from Rs 135.22 Cr last year. However, consolidated profit dipped to Rs 6.70 Cr from Rs 7.45 Cr in the same period a year ago.